{{Rsnum
|rsid=727479
|Gene=CYP19A1
|Chromosome=15
|position=51242350
|Orientation=minus
|GMAF=0.315
|Gene_s=CYP19A1,MIR4713
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 13.3 | 37.2 | 49.6
| HCB | 8.1 | 36.8 | 55.1
| JPT | 10.6 | 32.7 | 56.6
| YRI | 5.5 | 35.9 | 58.6
| ASW | 7.1 | 32.1 | 60.7
| CHB | 8.1 | 36.8 | 55.1
| CHD | 10.1 | 45.0 | 45.0
| GIH | 9.9 | 42.6 | 47.5
| LWK | 1.8 | 35.5 | 62.7
| MEX | 15.5 | 43.1 | 41.4
| MKK | 6.4 | 28.8 | 64.7
| TSI | 19.6 | 45.1 | 35.3
| HapMapRevision=28
}}{{PMID|19124504|OA=1
}} [[endometrial cancer]] [[rs727479]](A) odds ratio per allele of 1.08, 95% confidence interval of 1.02-1.14, and P = 0.009

{{PMID Auto
|PMID=19366906
|Title=BRCA1 Breast Cancer Risk Is Modified by CYP19 Polymorphisms in Ashkenazi Jews
}}

{{omim
|desc=CYTOCHROME P450, FAMILY 19, SUBFAMILY A, POLYPEPTIDE 1; CYP19A1
|id=107910
|rsnum=727479
}}
{{PMID Auto
|PMID=19789370
|Title=CYP19A1 Genetic Variation in Relation to Prostate Cancer Risk and Circulating Sex Hormone Concentrations in Men from the Breast and Prostate Cancer Cohort Consortium
|OA=1
}}

{{PMID|16733710|OA=1
}} Association analyses of CYP19 gene polymorphisms with height variation in a large sample of Caucasian nuclear families.

{{PMID|16782804|OA=1
}} Polymorphisms of estrogen-biosynthesis genes CYP17 and CYP19 may influence age at menarche: a genetic association study in Caucasian females.

{{PMID|17325027}} Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women.

{{PMID|18199708|OA=1
}} Haplotype analyses of CYP19A1 gene variants and breast cancer risk: results from the Shanghai Breast Cancer Study.

{{PMID|18245543}} A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma.

{{PMID|18622258|OA=1
}} Association of genetic polymorphisms in CYP19A1 and blood levels of sex hormones among postmenopausal Chinese women.

{{PMID|18667686|OA=1
}} Association of two common single-nucleotide polymorphisms in the CYP19A1 locus and ovarian cancer risk.

{{PMID|18941913|OA=1
}} Coffee intake, variants in genes involved in caffeine metabolism, and the risk of epithelial ovarian cancer.

{{PMID|19015200|OA=1
}} Polymorphisms in estrogen- and androgen-metabolizing genes and the risk of gastric cancer.

{{PMID|19064562|OA=1
}} Genetic variation in CYP19A1 and risk of breast cancer and fibrocystic breast conditions among women in Shanghai, China.

{{PMID|19794821|OA=1
}} Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women.

{{PMID|20144226|OA=1
}} A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole.

{{PMID Auto GWAS
|PMID=22675492
|Trait=None
|Title=Genome-wide association study of circulating estradiol, testosterone, and sex hormone-binding globulin in postmenopausal women.
|RiskAllele=C
|Pval=5E-7
|OR=0.1070
|ORtxt=None
|OA=1
}}

{{PMID Auto
|PMID=23129173
|Title=Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole
|OA=1
}}

{{PMID Auto
|PMID=23700878
|Title=Research on aromatase gene (CYP19A1) polymorphisms as a predictor of endocrine therapy effectiveness in breast cancer
}}

{{PMID Auto
|PMID=23669293
|Title=CYP19A1 gene polymorphisms and risk of lung cancer.
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}